Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386608 | 1.00 | ADORA3 (1.00) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1663612 | 0.89 | ADORA3 (1.00) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8111292 | 0.88 | ADORA3 (1.00) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1663767 | 0.87 | ADORA3 (1.00) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1666099 | 0.86 | ADORA3 (1.00) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1662148 | 0.86 | ADORA3 (1.00) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15124821 | 0.84 | ADORA3 (0.81) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8106742 | 0.83 | ADORA3 (1.00) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6379174 | 0.82 | ADORA3 (0.91) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8097486 | 0.82 | ADORA3 (0.86) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | claimed |
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | claimed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | claimed |
| EP-3452092-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-13 | — | — | EP | claimed |
| EP-3280414-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | Oxford University Innovation Limited (GB) | 2018-02-14 | — | — | EP | claimed |
| WO-2017191300-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-09 | — | — | WO | claimed |
| WO-2017178820-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-10-19 | — | — | WO | claimed |
| WO-2005079250-A2 | PURINES ARE SELF-RENEWAL SIGNALS FOR NEURAL STEM CELLS, AND PURINE RECEPTOR ANTAGONISTS PROMOTE NEURONAL AND GLIAL DIFFERENTIATION THEREFROM | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050181503-A1 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| EP-1096975-B1 | USE OF A3 ADENOSINE RECEPTOR ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRAOCULAR PRESSURE | UNIV PENNSYLVANIA (US) | 2005-03-16 | — | — | EP | claimed |
| JP-2004520404-A | — | — | 2004-07-08 | — | — | JP | claimed |
| EP-1363644-A2 | MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES | Can-Fite Biopharma Ltd. (IL) | 2003-11-26 | — | — | EP | claimed |
| US-20020165197-A1 | Administering adenosine receptor ligand | CAN-FITE BIOPHARMA LTD. (IL) | 2002-11-07 | — | — | US | claimed |
| WO-2002066020-A2 | MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES | CAN-FITE BIOPHARMA LTD. (IL) | 2002-08-29 | — | — | WO | claimed |
| US-20020115635-A1 | Modulation of GSK-3beta activity and its different uses | CAN-FITE TECHNOLOGIES LTD. (IL) | 2002-08-22 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2001019360-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ADENOSINE RECEPTOR AGONIST OR ANTAGONIST | CAN-FITE BIOPHARMA LTD. (IL) | 2001-03-22 | — | — | WO | disclosed |
| US-6066642-A | FOR SELECTIVELY BLOCKING THE A3 ADENOSINE RECEPTOR OF A MAMMAL | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-05-23 | — | — | US | disclosed |
| WO-2000003741-A2 | METHODS FOR REDUCING INTRAOCULAR PRESSURE USING A3-ADENOSINE ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ALDH1A1 1054/4885CYP1A2 398/4885 |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA3 3/4885ALDH1A1 1054/4885CYP1A2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.